Immunocore climbs on upbeat sales of eye cancer drug
10/08/2022 18:06
** Shares of Immunocore Holdings Plc IMCR.O rise 5.2% to
$54.43
** IMCR records $33.7 mln in Q2 sales of its drug, Kimmtrak,
which was approved in Europe in April to treat advanced uveal
melanoma - a type of eye cancer urn:newsml:reuters.com:*:nGNX3L81yk
** Kimmtrak in January received approval in the United
States for certain adult patients with advanced uveal melanoma
** Brokerage Cowen says the drug's sales 'crushed' Street
estimates of $15 mln in its first full quarter since launch
** Including session gains, stock up 59% YTD
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))